Collateral damage: Fear from SARS-CoV2-infection causing Takotsubo cardiomyopathy

Uhe, Tobias; Hagendorff, Andreas; Wachter, Rolf; Laufs, Ulrich

doi:10.1007/s00392-020-01706-w

Cited by 4 publications

(6 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After applying the eligibility criteria and title and abstract review followed by detailed evaluations, 67 articles were selected. 4 , 5 , 9 , 11 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , ...…”

Section: Resultsmentioning

confidence: 99%

Takotsubo syndrome and COVID‐19: A systematic review

Ghasemi

Kazemian

Nejadghaderi

et al. 2022

Health Science Reports

View full text Add to dashboard Cite

Background and Aims Takotsubo syndrome (TTS), also known as stress cardiomyopathy, is characterized by acute and transient left ventricular dysfunction and has increased during the COVID‐19 pandemic. Herein, we aim to review studies on TTS that were associated with COVID‐19 infection, vaccine, and other COVID‐19‐related etiologies including psychosocial stressors. Methods We systematically searched PubMed, EMBASE, and Scopus up to May 12, 2022. We included case reports, case series, and original articles that reported at least one TTS case associated with COVID‐19, or TTS cases after receiving COVID‐19 vaccines, or TTS cases secondary to psychological stress due to the COVID‐19 pandemic. The quality assessment was conducted using the Joanna Briggs Institute checklist. Results Sixty‐seven articles including 102 cases were included. Hypertension was the most frequently accompanying comorbidity ( N = 67 [65.6%]) and the mean left ventricular ejection fraction was 36.5%. Among COVID‐19 patients, the in‐hospital mortality rate was 33.3%. On the other hand, only one COVID‐19‐negative individual expired (2.3%). The most common presenting clinical symptom was dyspnea in 42 (73.6%) patients. the mean time interval from the first symptom to admission was 7.2 days. The most common chest imaging finding was ground‐glass opacity which was reported in 14 (31.1%) participants. The most common abnormalities were T‐wave inversion in 35 (43.2%) and ST‐segment elevation in 30 (37%). Brain natriuretic peptide and troponin were elevated in 94.7% and 95.9% of participants, respectively. Conclusion The TTS in patients with COVID‐19 is almost rare, whereas it could lead to a great mortality and morbidity. An individual with COVID‐19, especially an elderly woman, presented with dyspnea in addition to a rise in brain natriuretic peptide and troponin should be evaluated for TTS.

show abstract

Section: Resultsmentioning

confidence: 99%

Takotsubo syndrome and COVID‐19: A systematic review

Ghasemi

Kazemian

Nejadghaderi

et al. 2022

Health Science Reports

View full text Add to dashboard Cite

show abstract

“…Both emotional stress and physical stress by infection itself are considered as possible triggers of typical [83][84][85] as well as atypical [86] TTS in patients with COVID-19 (Table 3). Not only the COVID-19 patient, but also his or her family may develop TTS possibly as a result of stressful situations [87]. During the diagnostic work up, care should be taken to keep sonographers and doctors safe [88,89].…”

Section: Covid-19 and Ttsmentioning

confidence: 99%

Update of takotsubo syndrome in the era of COVID-19

Okura

2021

Journal of Cardiology

View full text Add to dashboard Cite

Highlights Takotsubo syndrome (TTS) has become a globally recognized disease and its spectrum has been widened based on the observations using multimodality images. Despite the long-standing clinical experience and efforts in basic research, its pathophysiology and specific treatments have not been well established. We should always remember possible cardiovascular complications such as coronary artery disease, thromboembolism, myocarditis, and TTS in patients with COVID-19.

show abstract

“…6 Clinical manifestations of TTS include anginal chest pain and dyspnea. 6 Creatine-kinase, troponin, catecholamines and proBNP are frequently elevated. Electrocardiography shows ST-elevation and negative T-waves.…”

Section: Sars-cov-2 Triggered Takotsubo In 38 Patientsmentioning

confidence: 99%

“…TTS predominantly affects females and is triggered by physical respectively emotional stress in one-third of the cases each. 6 Depending on the location of dyskinesia/akinesia/ hypokinesia, four types of TTS are delineated: the apical type, the mid-ventricular type, the basal type, and the global type. TTS mimics myocardial infarction clinically, chemically, and electrocardiographically.…”

Section: Sars-cov-2 Triggered Takotsubo In 38 Patientsmentioning

confidence: 99%

See 1 more Smart Citation

SARS‐CoV‐2 triggered Takotsubo in 38 patients

Finsterer

Stöllberger

2020

Journal of Medical Virology

View full text Add to dashboard Cite

female described by Meyer et al. 8 Since then, several other SARS-CoV-2 infected patients with TTS have been reported. In a patient reported by Chadha et al. TTS was triggered by the fear from becoming infected without being actually infected with SARS-CoV-2. This patient was not included in the current evaluation. Also the patient reported by Kir et al. was not included as echocardiography was normal throughout hospitalization. In 17 patients, TTS developed after onset of the SARS-CoV-2 infection, in two patients together with the infection, and in 19 patients onset of TTS was not reported (Table 1). Age ranged between 39 and 87 years among 19 patients. In 19 patients age was not reported. Ten patients were females, 9 were males, and in 19 patients gender was not reported. Fifteen patients presented with the classical type, two with the mid-ventricular type of TTS, and two patients with the basal type. In 19 patients, the TTS type was not reported (Table 1). Treatment for TTS was quite variable but most patients received betablockers, diuretics, heparin, or acetyl-salicylic acid (Table 1). Only a single patient received oral anticoagulation. One patient required pericardiocentesis because of immune-mediated pericarditis. 9 Thirteen patients recovered, four died, one patient improved, and in 20 patients the outcome was not reported (Table 1). Twenty-seven patients originated from Europe and 11 from the US. This mini-review shows that TTS can be associated with the SARS-CoV-2 infection but whether this association is accidental or causal remains speculative. There are indications that the general prevalence of SARS-CoV-2 associated TTS is not increased compared to the pre-COVID-10 era as reported by Jabri et al. and Delmas et al. Clinical presentation, epidemiology, treatment, and outcome of SARS-CoV-2-associated TTS is similar to COVID-19-unrelated TTS. In some patients, as reported by Sala et al., TTS may mimic myocarditis. TTS should be suspected in a SARS-CoV-2 infected patient if symptoms and signs of a myocardial infarction or heart failure develop in addition to the pulmonary compromise. In conclusion, TTS in the context of a SARS-CoV-2 infection is more frequent than anticipated. Whether the general prevalence of TTS is truly increased compared with non-COVID-19 times requires further investigations.

show abstract

Collateral damage: Fear from SARS-CoV2-infection causing Takotsubo cardiomyopathy

Cited by 4 publications

References 10 publications

Takotsubo syndrome and COVID‐19: A systematic review

Takotsubo syndrome and COVID‐19: A systematic review

Update of takotsubo syndrome in the era of COVID-19

SARS‐CoV‐2 triggered Takotsubo in 38 patients

Contact Info

Product

Resources

About